These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36614890)

  • 21. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.
    Mori S
    Mod Rheumatol; 2011 Dec; 21(6):621-7. PubMed ID: 21528424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010-2019).
    Brkic A; Diamantopoulos AP; Hoff M; Haavardsholm EA; Fevang BTS; Brekke LK; Loli L; Zettel C; Bakland G; Mielnik P; Haugeberg G
    BMC Health Serv Res; 2023 Sep; 23(1):968. PubMed ID: 37679747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R; Atzeni F; Sarzi Puttini P
    BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
    Ahn SS; Jung SM; Song JJ; Park YB; Park JY; Lee SW
    Yonsei Med J; 2018 May; 59(3):452-456. PubMed ID: 29611409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
    Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
    Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus reactivation in rheumatoid arthritis.
    Wu YL; Ke J; Zhang BY; Zhao D
    World J Clin Cases; 2022 Jan; 10(1):12-22. PubMed ID: 35071501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
    Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
    [No Abstract]   [Full Text] [Related]  

  • 32. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
    Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
    PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
    Kuo MH; Tseng CW; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
    Dig Dis Sci; 2021 Nov; 66(11):4026-4034. PubMed ID: 33387124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.
    Li S; Kaur PP; Chan V; Berney S
    Clin Rheumatol; 2009 Jul; 28(7):787-91. PubMed ID: 19291350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
    Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
    Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry.
    Koh JH; Lee Y; Kim HA; Kim J; Shin K
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221096363. PubMed ID: 35586514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
    Uhrenholt L; Christensen R; Dinesen WKH; Liboriussen CH; Andersen SS; Dreyer L; Schlemmer A; Hauge EM; Skrubbeltrang C; Taylor PC; Kristensen S
    Rheumatology (Oxford); 2022 Aug; 61(8):3107-3122. PubMed ID: 34864896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.
    Sayar S; Kürbüz K; Kahraman R; Öztürk O; Çalışkan Z; Doğanay HL; Özdil K
    Turk J Gastroenterol; 2020 Jul; 31(7):522-528. PubMed ID: 32897226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.